A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

A recent study published in JAMA Psychiatry has uncovered promising evidence suggesting that glucagon-like peptide-1 (GLP-1) ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced ...

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

(HealthDay News) — The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), a glucagon-like peptide-1 (GLP-1) receptor agonist ...

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

Liraglutide, the generic for Victoza, is similar to semaglutide, the active ingredient in the popular weight-loss drug Ozempic. The FDA supports the development of generic drugs, such as GLP-1s ...

These medications were sitagliptin, liraglutide, glimepiride, or insulin glargine U-100. Sitagliptin, liraglutide, and ...

Diabetes Care. 2015;38(6):1058-1066. The safety profile of liraglutide is under continuous surveillance through meticulous routine pharmacovigilance, with any cases of pancreatitis being analyzed ...

Only 34 of 79 websites stated that compounded drugs were not FDA approved; 39 websites did not report adverse effects, warnings.

Liraglutide, sold under the brand name Victoza for diabetes, is an earlier iteration in the same class as semaglutide, the active ingredient in Ozempic. Both are sold by Danish drug giant Novo ...